Other studies made a distinction between ductal carcinoma in situ (DCIS) and invasive carcinoma, suggesting that BNIP3 upregulation was correlated with higher risk of relapse and shorter disease-free survival only in DCIS (16). This evidence concerns the gene BNIP3 and ductal breast carcinoma in situ.